Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
A phase 3 trial testing Bexobrutideg in chronic lymphocytic leukaemia, now recruiting.
Overview
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL is a phase 3 interventional study registered as NCT07516093, led by Nurix Therapeutics, and recruiting when checked on 2026-09-11. Official title: A Phase 3, Randomised, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukaemia (CLL)/Small Lymphocytic Lymphoma (SLL). Planned enrolment is 620 participants (estimated). The study started in 2026-08-03 and primary completion is expected in 2029-10. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TrialA Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TrialICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentDZD8586
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentCTX112
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentICP-248
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentKRT-232
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentRocbrutinib
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.